Biocryst Pharmaceuticals (BCRX) Net Income Growth (3y) (2013 - 2026)
Biocryst Pharmaceuticals (BCRX) Net Income Growth (3y) (2013 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 89.78 Bn | 87.91 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 36.02 Bn | 32.28 Bn | 1.97 Bn | 51.28% |
| 3 | Zoetis | 32.60 Bn | 30.66 Bn | 1.62 Bn | 2.94% |
| 4 | Takeda Pharmaceutical | 27.54 Bn | 23.48 Bn | 4.39 Bn | -62.58% |
| 5 | United Therapeutics | 23.09 Bn | 20.94 Bn | 648.10 Mn | 4.50% |
| 6 | RedHill Biopharma | 21.48 Bn | 21.48 Bn | - | - |
| 7 | Viatris | 20.35 Bn | 18.54 Bn | 1.16 Bn | -7.75% |
| 8 | Neurocrine Biosciences | 17.82 Bn | 16.50 Bn | 800.70 Mn | 66.11% |
| 9 | Elanco Animal Health | 12.64 Bn | 12.21 Bn | 785.00 Mn | -17.90% |
| 10 | Biocryst Pharmaceuticals | 2.37 Bn | 2.30 Bn | 151.04 Mn | -138.31% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -138.31% |
| Dec 31, 2025 | 75.83% |
| Sep 30, 2025 | 32.06% |
| Jun 30, 2025 | 27.78% |
| Mar 31, 2025 | 26.00% |
| Dec 31, 2024 | -14.65% |
| Sep 30, 2024 | 37.97% |
| Jun 30, 2024 | 33.55% |
| Mar 31, 2024 | 18.05% |
| Dec 31, 2023 | 2.67% |
| Sep 30, 2023 | 7.79% |
| Jun 30, 2023 | -24.89% |
| Mar 31, 2023 | -12.38% |
| Dec 31, 2022 | -181.21% |
| Sep 30, 2022 | -4.06% |
| Jun 30, 2022 | -16.31% |
| Mar 31, 2022 | -33.11% |
| Dec 31, 2021 | 11.04% |
| Sep 30, 2021 | -24.83% |
| Jun 30, 2021 | -28.37% |